Τόμος 22 (2008) – Τεύχος 2 – Άρθρο 40 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 22 (2008) – Issue 2 – Article 40 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

Title Eph receptors and ephrin ligands: back to the origin in the therapy of cancer
Authors C. Hadjicosta and M. Mironidou-Tzouveleki

A’ Laboratory of Pharmacology, Medical School, Aristotle University of Thessaloniki, Greece

Citation Hadjicosta, C., Mironidou-Tzouveleki, M.: Eph receptors and ephrin ligands: back to the origin in the therapy of cancer, Epitheorese Klin. Farmakol. Farmakokinet. 22(2): 159-162 (2008)
Publication Date 23-25 May 2008
Full Text Language English
Order – Buy  Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €)

pharmakonpress[at]pharmakonpress[.]gr

Keywords Eph receptors, ephrin genes, ephrin ligants, cancer.
Other Terms Review article
Summary In the quest for the magic treatment of cancer, researchers implicate that our efforts must focus on the primary stages of tumor growth. In the complex molecular signaling pathways that are involved in the process of tumorigenesis and tumor progression, vascular functions are essential part. Eph receptors, the largest family of receptor tyrosine kinases (classified into A and B family according to corresponding ligands) and ephrin ligand seem to be the key players in arteriovenous differentiation during embryonic vascular development. Even though they were first identified as neuronal pathfinding molecules, the Eph/ephrin system appears to control tumor and vascular functions during tumor growth. They seem to be abnormally expressed in various human tumors (ovarian, lung, breast, melanoma, esophageal, colon, prostate, kidney, glioblastoma, neuroblastoma) and can be considered as ideal prognostic markers of chemotherapy/chemoprevention. Therefore Eph/ephrin system is a future molecular target for drugs. Furthermore through experimental work it seems that inhibition of Eph/ephrin system can be achieved with antibodies. New horizons are opened in this part of therapeutics of cancer, back to the early steps of the tumour development. 
References 1. Zhang S., Jiang T., Liang M.: Expression of Eph B4 and Ephrin B2 in cervical cancer tissues and angiogenesis. Int. J.  Gynecol. Obstr. 96(1): 46-47 (2007)

2. Castellvi J., Garcia A., De La Torre J., Hernandez J., Gil A., Xercavins J., Cajal Y R.S.: Ephrin B expression in epithelial ovarian neoplasms correlates with tumour differentiation and angiogenesis. Hum. Pathol. 37: 883-889 (2006)

3. Surawska H., Ma C.P., Salgia R.: The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor 15: 419-433 (2004)

4. Heroult M., Schaffner F., Augustin G.H.: Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumour progression. Exp. Cell Res. 312: 642-650 (2005)

5. Fox P.B., Kandpal P.R.: Invasiveness of breast carcinoma cells and transcript profile: Eph receptors and ephrin ligands as molecular markers of potential diagnostic and prognostic application. Biochem. Biophys. Res. Comm. 318: 882-892 (2004)

6. Poliakov A., Cotrina M, Wilkinson G.D.: Diverse roles of Eph receptors and ephrins in the regulation of cell migration and tissue assemply. Developmental Cell 7: 465-480 (2004)

7. Chen L., Aoto J.: Bidirectional ephrin/Eph signaling in synaptic functions. Brain Res. 12(1184): 72-80 (2007)

8. Wimmer-Kleikamp H.S., Lackmann M.: Eph-modulated cell morphology, adhesion and motility in carcinogenesis. Life 57: 421-431 (2005)

9. Kertesz N., Krasnoperov V., Reddy R., Leshanski L., Kumar R.S., Zozulya S., Gill S.P.: The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumour growth. Blood 107:  2330-2338 (2006)

10. Iiizumi M., Hosokawa M., Takehara A., Chung S., Naka-mura T., Katagiri T., Eguchi H., Ohigashi H., Ishikawa O., Nakamura Y., Nakagawa H.: EphA4 receptor, overexpressed in pancreatic ductal adenocarcinoma, promotes cancer cell growth. Cancer Sci 97: 1211-1216 (2006)

11. Nasreen N., Mohammed A.K., Antony B.V.: Silencing the receptor EphA2 suppresses the growth and haptotaxis of malignant mesothelioma cells. Cancer 107: 2425-2433 (2006)

Relative Papers

Online ISSN 1011-6575

Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:

Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor

Τι είναι η Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση-Οδηγίες προς τους Συγγραφείς – 
What is Epitheorese Klinikes Farmakologias 
και Farmakokinetikes-International Edition-Instrunctions to Authors

Άρθρα Δημοσιευμένα στην Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – 
Articles Published in Epitheorese Klinikes Farmakologias 
και Farmakokinetikes-International Edition

Συντακτικη Επιτροπή-Editorial Board

ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 2008 – ANNUAL SUBSCRIPTION 2008
Γλώσσα Πλήρους Κειμένου – Full Text Language Αγγλικά – English
Παραγγελία – Αγορά – Order – Buy Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €)

pharmakonpress[at]pharmakonpress[.]gr

Έντυπη Μορφή (70 € + έξοδα αποστολής) – Printed Type (70 € + shipping)

pharmakonpress[at]pharmakonpress[.]gr

 

 

Bookmark the permalink.

Comments are closed.